India's CDSCO Seeks Public Input on Drug Approval

What Is CDSCO Proposing for Drug Approval Reform?

The Central Drugs Standard Control Organisation, which operates under India's Ministry of Health and Family Welfare, has issued a call for public comment on regulatory practices that may have created disparities between how domestic and imported pharmaceutical products are evaluated. The consultation reflects long-standing concerns within the industry that approval timelines, data requirements, and post-marketing surveillance obligations have not been applied consistently across all market participants.

India serves as one of the world's largest producers of generic medicines and a major exporter of active pharmaceutical ingredients, making its regulatory framework particularly influential for global drug supply chains. By soliciting input on leveling the regulatory playing field, CDSCO signals an intent to modernize its approach in line with international harmonization initiatives led by bodies such as the International Council for Harmonisation (ICH), which India joined as a member in 2017.

Why Does Regulatory Harmonization Matter for Patients and Public Health?

When regulatory standards diverge across jurisdictions or between manufacturer types within a single country, the result can be uneven quality controls, delayed access to innovative medicines, and complications for international trade in pharmaceuticals. The World Health Organization has long advocated for regulatory convergence as a means of strengthening medicine safety globally, particularly in regions where regulatory capacity varies between national authorities.

For patients, harmonization typically translates into more predictable access to medicines that have undergone consistent safety and efficacy review. For the broader public health system, aligned regulatory frameworks reduce the risk of substandard or falsified medicines entering supply chains and facilitate faster responses to emerging therapeutic needs. The Asia-Pacific region, encompassing some of the fastest-growing pharmaceutical markets, has been a particular focus for harmonization efforts coordinated through forums such as the Asia-Pacific Economic Cooperation Regulatory Harmonization Steering Committee.

How Does India's Approach Compare With Other Regional Regulators?

Several Asia-Pacific regulators, including Japan's Pharmaceuticals and Medical Devices Agency (PMDA), South Korea's Ministry of Food and Drug Safety, and Australia's Therapeutic Goods Administration, have implemented frameworks closely aligned with ICH guidelines and routinely participate in joint review programs. Singapore's Health Sciences Authority and Thailand's Food and Drug Administration have similarly moved toward greater convergence with international standards.

India's consultation comes at a time when the country is also expanding its regulatory capacity through investments in state-level drug control authorities and enhanced inspection programs. Industry observers note that aligning domestic and foreign manufacturer requirements could strengthen India's position in global pharmaceutical trade negotiations while reducing compliance complexity for companies operating across multiple markets.